89 related articles for article (PubMed ID: 19635442)
1. [Opportunistic co-infection in a patient with Crohn's disease during infliximab (anti-TNFalpha) therapy].
Salavert M; Bastida G; Pemán J; Nos P
Rev Iberoam Micol; 2009 Sep; 26(3):213-7. PubMed ID: 19635442
[TBL] [Abstract][Full Text] [Related]
2. [Infectious risk].
Calabuig E; Salavert M
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone.
Singh SM; Rau NV; Cohen LB; Harris H
CMAJ; 2004 Oct; 171(9):1063-4. PubMed ID: 15505269
[TBL] [Abstract][Full Text] [Related]
4. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
5. Nocardia pneumonia in a patient with Crohn's disease receiving 6-mercaptopurine and infliximab.
Saleemuddin A; Govender P; Farraye FA
J Crohns Colitis; 2014 Jul; 8(7):708-9. PubMed ID: 24342764
[No Abstract] [Full Text] [Related]
6. [Meningitis due to Listeria monocytogenes as a complication of infliximab therapy].
Joosten AA; van Olffen GH; Hageman G
Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1470-2. PubMed ID: 12908351
[TBL] [Abstract][Full Text] [Related]
7. [Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis].
Pontikaki I; Gerloni V; Gattinara M; Luriati A; Salmaso A; De Marco G; Teruzzi B; Valcamonica E; Fantini F
Reumatismo; 2006; 58(1):31-8. PubMed ID: 16639486
[TBL] [Abstract][Full Text] [Related]
8. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis.
Bourikas LA; Kourbeti IS; Koutsopoulos AV; Koutroubakis IE
Gut; 2008 Mar; 57(3):425; author reply 425-6. PubMed ID: 18268059
[No Abstract] [Full Text] [Related]
9. Invasive pulmonary aspergillosis associated with infliximab therapy.
Warris A; Bjørneklett A; Gaustad P
N Engl J Med; 2001 Apr; 344(14):1099-100. PubMed ID: 11291675
[No Abstract] [Full Text] [Related]
10. [A case of acute and necrotizing cutaneous Mycobacterium marinum infection in a patient treated with infliximab for Crohn's disease].
Guyot A; Begon E; Abramowitz L; Landry J; Marinho E; Descamps V; Crickx B
Ann Dermatol Venereol; 2009 Nov; 136(11):806-10. PubMed ID: 19917434
[TBL] [Abstract][Full Text] [Related]
11. How to improve the safety of biologic therapy in Crohn's disease.
Ferkolj I
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
[TBL] [Abstract][Full Text] [Related]
12. Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease.
Vadikolias K; Kouklakis G; Heliopoulos I; Argyropoulou P; Papanas N; Tzilonidou M; Prassopoulos P; Piperidou H
Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):159-62. PubMed ID: 17273002
[TBL] [Abstract][Full Text] [Related]
13. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
Carroccio A; Di Prima L; Pirrone G; Ambrosiano G; Noto D; Cefalù AB
Recenti Prog Med; 2006 Feb; 97(2):108-12; quiz 122. PubMed ID: 16671277
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary nocardiosis in an adolescent patient with Crohn's disease treated with infliximab: a serious complication of TNF-alpha blockers.
Verma R; Walia R; Sondike SB; Khan R
W V Med J; 2015; 111(3):36-9. PubMed ID: 26050296
[TBL] [Abstract][Full Text] [Related]
16. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.
Esteve M; Saro C; González-Huix F; Suarez F; Forné M; Viver JM
Gut; 2004 Sep; 53(9):1363-5. PubMed ID: 15306601
[TBL] [Abstract][Full Text] [Related]
17. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
[TBL] [Abstract][Full Text] [Related]
18. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.
Moiton MP; Richez C; Dumoulin C; Mehsen N; Dehais J; Schaeverbeke T
Clin Microbiol Infect; 2006 Dec; 12(12):1151-3. PubMed ID: 17121619
[TBL] [Abstract][Full Text] [Related]
19. Fatal invasive pulmonary aspergillosis associated with adalimumab therapy.
Manz M; Beglinger C; Vavricka SR
Gut; 2009 Jan; 58(1):149. PubMed ID: 19091839
[No Abstract] [Full Text] [Related]
20. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.
Slifman NR; Gershon SK; Lee JH; Edwards ET; Braun MM
Arthritis Rheum; 2003 Feb; 48(2):319-24. PubMed ID: 12571839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
